Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.27

Shares of Kenvue Inc. (NYSE:KVUE) have received an average recommendation of “Hold” from the fifteen research firms that are currently covering the company, Marketbeat Ratings reports. Twelve research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $19.2727.

A number of research analysts recently commented on the stock. UBS Group decreased their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Barclays raised their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st.

Kenvue Stock Up 0.2%

NYSE:KVUE opened at $17.87 on Friday. The stock has a 50-day simple moving average of $18.92 and a 200 day simple moving average of $18.20. Kenvue has a 52-week low of $14.02 and a 52-week high of $20.13. The company has a market cap of $34.32 billion, a PE ratio of 20.54, a PEG ratio of 1.63 and a beta of 0.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the business earned $0.29 EPS. Kenvue’s revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 2nd. Shareholders of record on Monday, September 21st will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Hedge Funds Weigh In On Kenvue

A number of institutional investors have recently modified their holdings of the business. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the 4th quarter valued at $26,000. Johnson Financial Group Inc. bought a new position in shares of Kenvue in the 2nd quarter worth about $26,000. MV Capital Management Inc. purchased a new position in Kenvue during the 4th quarter valued at about $28,000. CoreCap Advisors LLC lifted its position in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares during the period. Finally, Reflection Asset Management bought a new stake in Kenvue during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.